GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $96,416.32 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $89.44, for a total value of $96,416.32. Following the completion of the transaction, the chief executive officer now owns 6,674 shares in the company, valued at approximately $596,922.56. This trade represents a 13.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Performance

Shares of GeneDx stock opened at $97.44 on Thursday. GeneDx Holdings Corp. has a 52 week low of $8.03 and a 52 week high of $115.60. The business’s fifty day simple moving average is $84.59 and its 200-day simple moving average is $70.97. The firm has a market cap of $2.73 billion, a PE ratio of -49.71 and a beta of 1.91. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

WGS has been the topic of a number of analyst reports. TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Investors Weigh In On GeneDx

Several institutional investors and hedge funds have recently modified their holdings of WGS. MCF Advisors LLC raised its holdings in shares of GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares during the period. Sterling Capital Management LLC raised its holdings in shares of GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at $28,000. Lazard Asset Management LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at $35,000. Finally, Comerica Bank purchased a new stake in shares of GeneDx in the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.